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Bispecific and bifunctional antibodies are attracting consid-
erable interest as innovative anti-cancer therapeutics, but
their ability to selectively localize at the tumor site has
rarely been studied by quantitative biodistribution studies
in immunocompetent animal models or in patients. Here,
we describe the production of a novel bifunctional antibody,
consisting of the F8 antibody (specific to the alternatively
spliced EDA domain of fibronectin) fused to the extracel-
lular portion of CD86 (co-stimulatory molecule B7.2).
However, the fusion molecule was unable to target tumors
in vivo. These data suggest that bispecific antibodies do not
always localize on tumors and should therefore be charac-
terized by imaging or biodistribution studies.
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Introduction
Bispecific and bifunctional antibodies represent a novel class
of anti-cancer biopharmaceuticals, which are developed with
the aim to activate an immune response at the tumor site,
while sparing normal organs (Hammond et al., 2007;
Nagorsen and Baeuerle, 2011; Pasche and Neri, 2012).
Several bispecific antibody formats have been considered
and a number of products have been moved to clinical trials
(Kontermann, 2005). Promising therapeutic results have re-
cently been reported for clinical trials in patients with
advanced hematological malignancies (Topp et al., 2011).
Similarly, the field of ‘immunocytokines’ (i.e. antibody-
cytokine fusion proteins) has rapidly advanced. Several
immunocytokines have been tested in preclinical models of
cancer and nine products have been moved to Phase I/II clin-
ical trials (Kontermann, 2012; Pasche and Neri, 2012), with
promising results for the treatment of metastatic melanoma
(Eigentler et al., 2011).
In our lab, we have extensively studied many immunocyto-
kines in quantitative biodistribution studies in tumor-bearing
mice, using radioiodinated protein preparations and antibodies
of proven tumor-targeting performance. While fusion proteins
based on certain cytokines or growth factors, such as interleu-
kins (IL, e.g., IL2, IL12, IL15), tumor necrosis factor (TNF),
vascular endothelial growth factor (VEGF, e.g., VEGF-120) and
granulocyte-macrophage colony-stimulating factor (GM-CSF)
retained the excellent tumor-targeting properties of the parental
antibody, other immunocytokines or bifunctional proteins (e.g.
those based on interferon (IFN)-g, trans-acting activator of tran-
scription (TAT) peptides, calmodulin or dual cytokine fusions)
completely abrogated tumor targeting at pharmacologically
relevant concentrations, while being fully immunoreactive in
vitro and displaying good pharmaceutical quality in biochem-
ical assays (e.g. sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and gel-filtration analysis)
(Pasche and Neri, 2012).
To our knowledge, there is only one report in the literature
describing biodistribution studies of a bispecific antibody
(Stork et al., 2009). Unfortunately, the study provides little
information about the tumor-targeting properties of the
product, as it was performed in immunocompromised mice.
In principle, a bispecific antibody capable of avid binding to
circulating leukocytes (e.g. T-cells) should have problems ex-
travasating and reaching tumor cells outside the vascular
compartment.
Performing biodistribution studies with bispecific
antibodies is technically challenging, as it is difficult to dem-
onstrate that both antibody moieties display full immunoreac-
tivity. Indeed, in certain bispecific antibody formats, variable
domains may swap pairing, thus leading to a set of mole-
cules with reduced immunoreactivity (Little and Kipriyanov,
2007; Molhoj et al., 2007). Furthermore, it is difficult to
measure the immunoreactivity towards antigens, which are
not available as pure protein, and which cannot be used in
affinity chromatography procedures (e.g. CD3 components).
In order to generate and characterize the properties of a
bifunctional antibody molecule, with avid binding to T-cells
and to a validated tumor-associated antigen, we fused the F8
antibody (specific to the alternatively spliced EDA domain
of fibronectin, a marker of tumor angiogenesis; Rybak et al.,
2007; Villa et al., 2008) with the extracellular portion of
murine CD86 (B7.2; Sharpe and Freeman, 2002). B7.2 binds
to CD28 on T-cells with a dissociation constant Kd ¼ 20 mM
(Collins et al., 2002). When avidity effects come into play,
due to the multivalent display of CD28 and CD86 on the cell
membrane, the functional affinity of the interaction increases.
Similarly, anti-CD3 antibody (Dreier et al., 2002) moieties
with Kd values in the 0.1 mM range have extensively been
used for the preparation of bispecific antibodies (Kipriyanov
et al., 1999; Brischwein et al., 2006).
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The binding properties of B7.2-based bispecific fusion
proteins can be readily tested by affinity chromatography,
using the tumor-associated antigen or murine CTLA-4
immobilized on resin (Eagar et al., 2002).
In our study, we observed that the F8 antibody efficiently
targets tumors in vivo, but completely loses its tumor-
targeting ability when fused to murine B7.2. These data
suggest that the analysis of the tumor-targeting properties of
bispecific and bifunctional antibodies by quantitative biodis-
tribution studies should represent an essential activity in
product development strategies, since therapeutic perform-
ance correlates with the ability of the biopharmaceutical to
localize at the site of disease (Carnemolla et al., 2002; Halin
et al., 2002b; Wagner et al., 2008).
Methods
Cell lines and mouse tumor model
HEK 293 cells (CRL-1573, ATCC) were cultured in
Freestyle 293 expression medium (Gibco) containing 0.1%
Pluronic F68 (Sigma) in a shaker incubator at 378C and 5%
CO2. The murine teratocarcinoma F9 cell line (CRL-1720,
ATCC) was cultured as described before (Pasche et al.,
2011). Female 129SvPas and Balb/c nude mice were
obtained from Charles River (Germany).
Cloning and protein expression
The gene structure for SIP(F8) and for the F8 diabody (Villa
et al., 2008) has been previously described. F8-B7.2 contains
the extracellular domain of murine B7.2 (gene from Source
BioScience) sequentially fused to the diabody (Pasche et al.,
2011).
The fusion protein was expressed using transient gene ex-
pression in HEK-293 cells (Backliwal et al., 2008) and puri-
fied by protein A chromatography. The purified protein was
analyzed by SDS-PAGE before and after deglycosylation
with PNGase F (NEB), size exclusion chromatography
(Superdex200 10/300GL, GE Healthcare), BIAcore on a
EDA antigen-coated sensor chip and immunofluorescence
staining of F9 tumor sections as previously described
(Pasche et al., 2011).
Biodistribution studies
The in vivo targeting performance was assessed by quantita-
tive biodistribution studies as described before (Pasche et al.,
2011) and 15 mg of radioiodinated F8-B7.2 was injected into
the tail vein of tumor-bearing mice. Mice were sacrificed at
different time points after injection. Experiments were per-
formed under a project license granted by the Veterinaeramt
des Kantons Zurich (169/2008).
Fig. 1. Cloning, expression and characterization of F8-B7.2. (a) Schematic representation of the cloning strategy of F8-B7.2. Lead Seq, leader sequence
peptide; VH, VL, variable heavy and light chain. (b) Domain assembly of Sip (F8), diabody (F8) and F8-B7.2. (c) SDS-PAGE analysis of purified F8-B7.2.
MW, molecular marker; 1, F8-B7.2; 2, deglycosylated F8-B7.2; NR, R, non-reducing and reducing conditions. (d) Gel filtration analysis of affinity-purified
F8-B7.2. 1, Thyroglobulin 669 kDa; 2, BSA 67 kDa; 3, b-lactoglobulin 35 kDa. (e) Immunofluorescence analysis of murine F9 tumors. Tumor sections were
stained with a biotinylated F8-B7.2 (green, Alexa488) and an anti-CD31 antibody (red, Alexa594). Magnification 20, scale bars ¼ 100 mm. (f ) BIAcore
analysis of purified F8-B7.2 on an EDA-coated sensor chip. (g) BIAcore analysis of F8-B7.2 on a CTLA-4-Fc-coated sensor chip. (h) Immunoreactivity of
125I-SIP (F8) and 125I-F8-B7.2 on EDA-resin and on CTLA-4-Fc-resin: 1, 125I-SIP (F8) on CTLA-4-Fc-resin (n ¼ 3); 2, 125I-SIP (F8) on EDA-resin (n ¼ 3); 3,




CNBr-activated sepharose (GE Healthcare) was coupled to
EDA or to murine CTLA-4-Fc. The retention of radioiodi-
nated F8-B7.2 on resin was analyzed by affinity chromatog-
raphy, as described (Pasche et al., 2011).
Results and discussion
The fusion protein F8-B7.2 was expressed in non-covalent
homodimeric ‘diabody’ format (Fig. 1a and b), leading to fully
immunoreactive products with bivalent (i.e. avid) tumor
binding and long residence time on neoplastic lesions in vivo
(Pasche and Neri, 2012). The corresponding F8 antibody, in
diabody format and in Small Immune Protein (SIP) format
(Fig. 1b), has been extensively studied in biodistribution experi-
ments (Villa et al., 2008). F8-B7.2 was purified to homogeneity
by affinity chromatography and was well behaved in
SDS-PAGE (Fig. 1c and d). The fusion protein displayed a
high degree of N-linked glycosylation, as evidenced by
SDS-PAGE analysis before and after N-glycanase treatment.
F8-B7.2 stained neo-vascular structures in F9 murine tumors
(Fig. 1e) and displayed full retention of immunoreactivity in
BIAcore (Fig. 1f and g) and in affinity chromatography proce-
dures with immobilized EDA domain of fibronectin or immobi-
lized murine CTLA-4-Fc fusion (Fig. 1h).
When tested in biodistribution studies in immunocompe-
tent (Fig. 2a) and in nude mice (Fig. 2b) carrying subcutane-
ously grafted F9 tumors, a radioiodinated preparation of
F8-B7.2 failed to preferentially localize on the tumor 24 h
after intravenous (i.v.) injection, while the F8 antibody in
SIP format (Fig. 2a and b) and in diabody format (Villa
et al., 2008) efficiently targeted the neoplastic lesions.
Biodistributions at earlier time points (e.g. 15 min after i.v.
injection; Fig. 2c) revealed that the majority of the protein
had already been excreted via the hepatobiliary route, while
never reaching the cognate antigen in vivo, which is localized
on the abluminal side of tumor blood vessels (Rybak et al.,
2007; Villa et al., 2008).
The selective localization of antibody-fusion proteins to
the site of disease in vivo is strictly dependent on the pay-
loads that are attached to the antibody. Our group observed
that highly charged payloads (e.g. Calmodulin (Melkko
et al., 2002), VEGF-164 (Halin et al., 2002a) and HIV-1
TAT peptides (Niesner et al., 2002)), bulky payloads (Gafner
et al., 2006) and payloads prone to receptor trapping when
administered at low doses (e.g. IFNg; Ebbinghaus et al.,
2005) can completely abrogate tumor targeting.
Our data suggest that it is not obvious that a bifunctional
protein with avid binding to circulating leukocytes would
efficiently extravasate and reach a tumor-associated antigen
in vivo, even if the parental antibody displays good tumor-
targeting properties. In the case of F8-B7.2, the tumor-targeting
process does not take place even in immunocompromised mice
and is prevented by the rapid clearance from blood through the
liver. Due to its heavily glycosylated nature, the fusion protein
is subject to binding by carbohydrate-recognizing receptors on
hepatocytes and the resulting efficient and fast blood clearance
rate prohibits the targeting to the site of disease.
Some bispecific and bifunctional antibodies have demon-
strated a dramatic therapeutic activity in certain clinical trials
and it is possible that even small amounts of therapeutic
protein, delivered at the site of disease, may mediate a potent
anti-tumoral immune response. However, there is ample evi-
dence that efficient tumor localization of bifunctional anti-
bodies correlates with therapeutic performance and a
quantitative biodistribution study of targeting should repre-
sent an essential requirement for future product development
in this field.
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Fig. 2. Biodistribution study of radioiodinated F8-B7.2. Mice bearing
subcutaneous F9 teratocarcinoma were injected i.v. with 15 mg radiolabeled
protein. (a) Immunocompetent 129SvPas mice injected with 125I-SIP (F8)
(black bar, n ¼ 5) or with 125I-F8-B7.2 (gray bar, n ¼ 4). Mice were
sacrificed after 24 h. (b) Nude mice injected with 125I-SIP (F8) (black bar,
n ¼ 5) or with 125I-F8-B7.2 (gray bar, n ¼ 4). Mice were sacrificed after
24 h. (c) Nude mice injected with 125I-F8-B7.2 (n ¼ 4). Mice were sacrificed
after 15 min. Organs were excised and radioactivity counted, expressing
results as percent of injected dose per gram of tissue (%ID/g+SE).
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